ReWalk Robotics (NASDAQ:LFWD) versus Enovis (NYSE:ENOV) Head-To-Head Comparison

ReWalk Robotics (NASDAQ:LFWD) and Enovis (NYSE:ENOV) are both computer and technology companies, but which is the better investment? We will contrast the two companies based on the strength of their valuation, analyst recommendations, profitability, dividends, earnings, risk and institutional ownership.

Risk & Volatility

ReWalk Robotics has a beta of 2.05, meaning that its stock price is 105% more volatile than the S&P 500. Comparatively, Enovis has a beta of 1.94, meaning that its stock price is 94% more volatile than the S&P 500.

Profitability

This table compares ReWalk Robotics and Enovis’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
ReWalk Robotics	-77.21%	-43.02%	-31.53%
Enovis	-5.95%	4.39%	2.80%

Institutional and Insider Ownership

26.8% of ReWalk Robotics shares are owned by institutional investors. Comparatively, 98.5% of Enovis shares are owned by institutional investors. 2.5% of ReWalk Robotics shares are owned by company insiders. Comparatively, 2.4% of Enovis shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Valuation and Earnings

This table compares ReWalk Robotics and Enovis”s revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ReWalk Robotics	$13.85 million	0.89	-$22.13 million	($2.49)	-0.56
Enovis	$1.71 billion	1.47	-$33.26 million	($2.19)	-20.13

ReWalk Robotics has higher earnings, but lower revenue than Enovis. Enovis is trading at a lower price-to-earnings ratio than ReWalk Robotics, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a breakdown of current ratings for ReWalk Robotics and Enovis, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
ReWalk Robotics	0	0	1	1	3.50
Enovis	0	1	6	0	2.86

ReWalk Robotics presently has a consensus price target of $13.00, indicating a potential upside of 828.57%. Enovis has a consensus price target of $65.86, indicating a potential upside of 49.38%. Given ReWalk Robotics’ stronger consensus rating and higher probable upside, equities research analysts plainly believe ReWalk Robotics is more favorable than Enovis.

Summary

Enovis beats ReWalk Robotics on 8 of the 15 factors compared between the two stocks.

About ReWalk Robotics

ReWalk Robotics Ltd., a medical device company, designs, develops, and commercializes technologies that enable mobility and wellness in rehabilitation and daily life for individuals with physical and neurological conditions in the United States, Europe, the Asia-Pacific, and internationally. It offers ReWalk personal exoskeleton and rehabilitation exoskeleton devices; ReStore, a soft exo-suit intended for use in the rehabilitation of individuals with lower limb disability due to stroke; AlterG Anti-Gravity System for use in physical and neurological rehabilitation and athletic training; MyoCycle devices; and ReBoot, a personal soft exo-suit for home and community use by individuals post-stroke. The company markets and sells its products directly to institutions and individuals, as well as through third-party distributors. The company was formerly known as Argo Medical Technologies Ltd. ReWalk Robotics Ltd. was incorporated in 2001 and is headquartered in Yokneam Illit, Israel.

About Enovis

Enovis Corporation operates as a medical technology company focus on developing clinically differentiated solutions worldwide. It also manufactures and distributes medical devices which are used for reconstructive surgery, rehabilitation, pain management, and physical therapy. The company operates through Prevention and Recovery, and Reconstructive segments. Its Prevention and Recovery segment offers orthopedic solutions and recovery sciences including rigid and soft orthopedic bracing, hot and cold therapy, bone growth stimulators, vascular therapy systems and compression garments, therapeutic shoes and inserts, electrical stimulators management, and physical therapy products which are used by orthopedic specialists, surgeons, primary care physicians, pain management specialists, physical therapists, podiatrists, chiropractors, athletic trainers, and other healthcare professionals. The company's Reconstructive segment operates surgical implant business, which includes a suite of reconstructive joint products for the hip, knee, shoulder, elbow, foot, ankle, and finger, as well as surgical productivity tools. The company distributes its products through independent distributors and directly under the ESAB and DJO brands. Enovis Corporation was formerly known as Colfax Corporation. The company was founded in 1995 and is headquartered in Wilmington, Delaware.